Christineil Thompson1, Sydney Ariagno1, Mira A Kohorst2. 1. Department of Pediatric and Adolescent Medicine, Division of Pediatric Hematology-Oncology, Mayo Clinic, 200 First Street Southwest, Rochester, MN, 55905, USA. 2. Department of Pediatric and Adolescent Medicine, Division of Pediatric Hematology-Oncology, Mayo Clinic, 200 First Street Southwest, Rochester, MN, 55905, USA. Kohorst.mira@mayo.edu.
Abstract
PURPOSE OF REVIEW: Advances in the understanding of germline predisposition to pediatric cancers, particularly myeloid neoplasms, have increased rapidly over the last 20 years. Here, we highlight the most up-to-date knowledge regarding known pathogenic germline variants that contribute to the development of myeloid neoplasms in children. RECENT FINDINGS: This discussion enumerates the most notable myeloid neoplasm-causing germline mutations. These mutations may be organized based on their molecular underpinnings-transcriptional control, splicing and signal transduction control, and a group of heterogeneous bone marrow failure syndromes. We review recent findings related to the biochemical mechanisms that predispose to malignant transformation in each condition. Key genetic discoveries such as novel mutations, degrees of penetrance, principles of the two-hit hypothesis, and co-occurrence of multiple mutations are shared. Clinical pearls, such as information regarding epidemiology, natural history, or prognosis, are also discussed. Germline mutations predisposing to pediatric myeloid neoplasms are frequent, but underrecognized. They hold major clinical implications regarding prognosis, treatment strategies, and screening for other malignancies. Further research is warranted to better characterize each of these conditions, as well as identify additional novel germline pathogenic variants of interest.
PURPOSE OF REVIEW: Advances in the understanding of germline predisposition to pediatric cancers, particularly myeloid neoplasms, have increased rapidly over the last 20 years. Here, we highlight the most up-to-date knowledge regarding known pathogenic germline variants that contribute to the development of myeloid neoplasms in children. RECENT FINDINGS: This discussion enumerates the most notable myeloid neoplasm-causing germline mutations. These mutations may be organized based on their molecular underpinnings-transcriptional control, splicing and signal transduction control, and a group of heterogeneous bone marrow failure syndromes. We review recent findings related to the biochemical mechanisms that predispose to malignant transformation in each condition. Key genetic discoveries such as novel mutations, degrees of penetrance, principles of the two-hit hypothesis, and co-occurrence of multiple mutations are shared. Clinical pearls, such as information regarding epidemiology, natural history, or prognosis, are also discussed. Germline mutations predisposing to pediatric myeloid neoplasms are frequent, but underrecognized. They hold major clinical implications regarding prognosis, treatment strategies, and screening for other malignancies. Further research is warranted to better characterize each of these conditions, as well as identify additional novel germline pathogenic variants of interest.
Authors: Prajwal Boddu; Hagop M Kantarjian; Guillermo Garcia-Manero; Farhad Ravandi; Srdan Verstovsek; Elias Jabbour; Gautam Borthakur; Marina Konopleva; Kapil N Bhalla; Naval Daver; Courtney D DiNardo; Christopher B Benton; Koichi Takahashi; Zeev Estrov; Sherry R Pierce; Michael Andreeff; Jorge E Cortes; Tapan M Kadia Journal: Blood Adv Date: 2017-07-19
Authors: Daniel A Arber; Attilio Orazi; Robert Hasserjian; Jürgen Thiele; Michael J Borowitz; Michelle M Le Beau; Clara D Bloomfield; Mario Cazzola; James W Vardiman Journal: Blood Date: 2016-04-11 Impact factor: 22.113
Authors: Kiran Tawana; Jun Wang; Aline Renneville; Csaba Bödör; Robert Hills; Chey Loveday; Aleksandar Savic; Frederik W Van Delft; Jennifer Treleaven; Panayiotis Georgiades; Elizabeth Uglow; Norio Asou; Naokuni Uike; Maruša Debeljak; Janez Jazbec; Philip Ancliff; Rosemary Gale; Xavier Thomas; Valerie Mialou; Konstanze Döhner; Lars Bullinger; Beatrice Mueller; Thomas Pabst; Matthias Stelljes; Brigitte Schlegelberger; Eva Wozniak; Sameena Iqbal; Jessica Okosun; Shamzah Araf; Anne-Katrine Frank; Felicia B Lauridsen; Bo Porse; Claus Nerlov; Carolyn Owen; Inderjeet Dokal; John Gribben; Matthew Smith; Claude Preudhomme; Claude Chelala; Jamie Cavenagh; Jude Fitzgibbon Journal: Blood Date: 2015-07-10 Impact factor: 22.113
Authors: Saumya E Samaraweera; Paul P S Wang; Ka Leung Li; Debora A Casolari; Jinghua Feng; Mark Pinese; Kyaw Ze Ya Maung; Paul Leo; Mark Cowley; Kelly Perkins; Amanda M Smith; Jonathan Ellis; Amilia Wee; Devendra K Hiwase; Hamish S Scott; Andreas W Schreiber; Anna L Brown; Andrew J Deans; David M Ross; Andrew S Moore; Thomas J Gonda; Christopher N Hahn; Richard J D'Andrea Journal: Blood Date: 2021-12-02 Impact factor: 22.113
Authors: Alexander Arthur Wurm; Polina Zjablovskaja; Miroslava Kardosova; Dennis Gerloff; Daniela Bräuer-Hartmann; Christiane Katzerke; Jens-Uwe Hartmann; Touati Benoukraf; Stephan Fricke; Nadja Hilger; Anne-Marie Müller; Marius Bill; Sebastian Schwind; Daniel G Tenen; Dietger Niederwieser; Meritxell Alberich-Jorda; Gerhard Behre Journal: Nat Commun Date: 2017-06-29 Impact factor: 14.919